Chelation therapy drug is an established treatment for heavy metal toxicity. Chelation therapy agents that remove toxic metal ions such as Lead, Nickel, Zinc, iron and copper from the body by removing them from intracellular or extracellular spaces. The present study create all the experiment were performed at different temperature (303, 308, 313, 318, 323)°K. The UV-Vis measurements were carried out for the metal-drug complex by Spectrophotometric method. The absorption Spectrum of the mixture of drug and Nickel ion shows a batho chromic (red) shift in ?max, the absorbance change caused by complex arrangement between the Nickel ion and drug. The stoichiometry of the formed complex was investigated by the method of continuous variation and it was found (1:1), In the present work we investigate the stability constant of therapy drug with Ni(II) ion using water at (298K, 303, 308K, 313, 318)°K, We employed to determine (Ni(II) - ligand) complex stability constant (logK) values. It is observed that Ni (II) ion forms 1:1 complex. The thermodynamic parameter ?Go, ?Ho and ?So were calculated from values of stability constant at different temperatures. The formations of (Ni(II) –drug) complex were found to be spontaneous and indothermic in nature. Chemical kinetics show, the Complication of drug with Ni ion was found to follow the second order reaction.
Cite this article:
Huda N. Al-Ani. Removal of Toxic heavy metal ions by the formation of complex with Theophylline (Therapy drug): Thermodynamic and kinetic study. Research J. Pharm. and Tech 2021; 14(3):1693-1698. doi: 10.5958/0974-360X.2021.00301.2
Huda N. Al-Ani. Removal of Toxic heavy metal ions by the formation of complex with Theophylline (Therapy drug): Thermodynamic and kinetic study. Research J. Pharm. and Tech 2021; 14(3):1693-1698. doi: 10.5958/0974-360X.2021.00301.2 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-3-90
1. Crini G. “Recent Developments in Polysaccharide–Base Materials used as Adsorbents in Wastewater Treatment”. Progress in Polymer Science, 2005; (30): 38-70.
2. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends in pharmacological sciences. 2002; (23): 136-139.
3. Burd G I, Dixon D G and Glick B R. Plant growth-promoting bacteria that decrease heavy metal toxicity in plants. Canadian journal of microbiology. 2000; (46): 237-245.
4. Das K K, Das S N, Dhundasi S A. Nickel, its adverse health effects and oxidative stress. Indian journal medical research. 2008; 128(4): 25-412.
5. Nielsen F H. Biochemistry of the essential ultrace elements. third Edition. Plenum press, New York. 2013; pp293-308.
6. Andersen O. Principles and recent developments in chelation treatment of metal intoxication. Chem. Rev. 1999; 99: 2683-2710.
7. Jones M M. Design of new chelating agents for removal of intracellular toxic metals. In Coordination Chemistry: A Century of Progress; Kauffman G B., Ed.; The American Chemical Society: Washington, DC, USA.1994; pp. 427-438.
8. Walshe J M. Treatment of Wilsons-disease with trientine (Triethylene Tetramine) dihydrochloride. Lancet. 1982; 1(73):643–647.
9. Atwood IV K C, Woeckner E, Baratz R S and Sampson W I. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned. The Medscape Journal of Medicine. 2008; 10: 115-119.
10. Flora S J, and Pachauri V. Chelation in metal intoxication. International journal of environmental research and public health. 2010; 7: 2745- 2788.
11. Kosnett M. Chelation for heavy metals (Nickel, lead, and mercury): protective or perilous and Clinical Pharmacology & Therapeutics. 2010; 88:412-415.
12. Soares FA, Farina M, Santos FW, Souza D, Rocha JB, Nogueira CW. Interaction between metals and chelating agents affects glutamate binding on brainsynaptic membranes. Neurochem Res 2003; 28(12):1859–65.
13. Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminum chelating drugs. Toxicol Lett1995; 80(1-3):1-18.
14. Andersen O, Aaseth J. Molecular mechanisms of in vivo metal chelation: implications for clinical treatment of metal intoxications. Environ Health Perspect.2002; 110 (Suppl 5):887-90.
15. Rawson J M, Alberola A and Whalley A. Thiazyl radicals: old materials for new molecular devices. Journal of Materials Chemistry. 2006; 16: 2560-2575.
16. Eugen, C.A. Spectrophotometry: principle and applications. In Workshop Environment. 2013; pp 94-100.
17. Sommer L. Analytical absorption spectrophotometry in the visible and ultraviolet: the principles. (Elsevier). 2012; pp 75-89.
18. Bakhle Y S. Cox-2 and cancer: a new approach to an old problem. Br. J. Pharmacol. 2001; 134:1137-1150.
19. Combaret L. Molecular Mechanisms in Exercise-Induced Cardio protection. Journal of Physiology. 2000; 569 : 123-127.
20. Gibson R.E. and Loeffle O E. Absorption and Luminescence of Aromatic Molecules. American Chemistry of Society. 2009; 62 : 1324-1329.
21. Stephen L. Chem1 Virtual. Second Edition. Burnaby - Vancouver, Canada; 2004.
22. Ewing G W. Instrumental methods of chemical analysis. McGraw-Hill Inc., New York; 1990.
23. Kieffer, In Metals and Compounds in the Environment (G. Merian (ed)), VCH Weinheim.(1991); p. 481.
24. Atikins P W. Physical Chemistry. Eighth Edition. Oxford, Oxford University Press. Chicago. 2006.
25. Karlsson B C, Iian A. and Nicholls S. The spectrophysics of warfarin: Implications for protein binding. Journal of Physical Chemistry, 2007; 111, pp: 1052-1052.
26. Ramandeep Kaur, Sekhon B S. J Indian Chem Soc.2006; 83:645-650.
27. Boza J. Free and protein-bound glutamine have identical splanchnic extraction in healthy human volunteers, American journal of physiology. 2001; 281 (1): pp 267-274.